Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

141. Submassive pulmonary embolism. (Abstract)

Submassive pulmonary embolism. The US Surgeon General estimates that 100,000 to 180,000 deaths occur annually from acute pulmonary embolism (PE) in the United States. The case of Ms A, a 60-year-old woman with acute PE and right ventricular dysfunction (submassive PE), illustrates the clinical challenge of identifying this high-risk patient population and determining when more aggressive immediate therapy should be pursued in addition to standard anticoagulation. The clinical examination (...) , electrocardiogram, cardiac biomarkers, chest computed tomography, and echocardiography can be used to risk stratify patients with acute PE. Current options for more aggressive intervention in the treatment of patients with acute PE who are at increased risk of an adverse clinical course include systemic fibrinolysis, pharmacomechanical catheter-directed therapy, surgical pulmonary embolectomy, and inferior vena cava filter insertion. Determination of the optimal duration of anticoagulation and lifestyle

2013 JAMA

142. Cohort study: Pretest probability assessment combined with point-of-care D-dimer testing allows primary care physicians to rule out pulmonary embolism

Cohort study: Pretest probability assessment combined with point-of-care D-dimer testing allows primary care physicians to rule out pulmonary embolism Pretest probability assessment combined with point-of-care D-dimer testing allows primary care physicians to rule out pulmonary embolism | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we (...) physicians to rule out pulmonary embolism Article Text Diagnosis Cohort study Pretest probability assessment combined with point-of-care D-dimer testing allows primary care physicians to rule out pulmonary embolism Christopher Kabrhel Statistics from Altmetric.com Commentary on: Geersing GJ , Erkens PM , Lucassen WA , et al . Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. Context A Bayesian combination of pretest

2013 Evidence-Based Medicine

143. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) Overview | Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | Guidance | NICE Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism Technology appraisal guidance [TA287] Published date: 26 June 2013 Share Save Guidance on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein (...) thrombosis or pulmonary embolism in adults. Guidance development process Is this guidance up to date? . We found nothing new that affects the recommendations in this guidance. Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations. Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected

2013 National Institute for Health and Clinical Excellence - Technology Appraisals

144. Randomised controlled trial: Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment

Randomised controlled trial: Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment Article Text

2013 Evidence-Based Medicine

145. Cardiovascular Risk Assessment of Pulmonary Embolism With the GRACE Risk Score (Abstract)

Cardiovascular Risk Assessment of Pulmonary Embolism With the GRACE Risk Score Despite the existence of several risk scores, the accurate prediction of the prognosis in pulmonary embolism (PE) remains a challenge. The Global Registry of Acute Coronary Events (GRACE) risk score has a high diagnostic performance for adverse outcomes in acute coronary syndrome. We aimed to assess the applicability and extend the use of the GRACE risk score to PE. A case-control study of 206 consecutive patients (...) admitted with PE was performed. The GRACE, Geneva, Simplified Pulmonary Embolism Severity Index, Shock Index, and European Society of Cardiology risk scores were tested for the prediction of the primary end point: all-cause 30-day mortality. Comparisons between GRACE and the other risk scores were performed using receiver operating characteristic area under the curve and the integrated discrimination improvement index. All-cause 30-day mortality was observed in 18.9% of the patients. Unlike the other

2013 EvidenceUpdates

146. Moderate Pulmonary Embolism Treated With Thrombolysis (from the MOPETT Trial) (Abstract)

Moderate Pulmonary Embolism Treated With Thrombolysis (from the MOPETT Trial) The role of low-dose thrombolysis in the reduction of pulmonary artery pressure in moderate pulmonary embolism (PE) has not been investigated. Because the lungs are very sensitive to thrombolysis, we postulated that effective and safe thrombolysis might be achieved by a lower dose of tissue plasminogen activator. The purpose of the present study was to evaluate the role of this "safe dose" thrombolysis (...) in the reduction of pulmonary artery pressure in moderate PE. During a 22-month period, 121 patients with moderate PE were randomized to receive a "safe dose" of tissue plasminogen activator plus anticoagulation (thrombolysis group [TG], n = 61 patients) or anticoagulation alone (control group [CG], n = 60). The primary end points consisted of pulmonary hypertension and the composite end point of pulmonary hypertension and recurrent PE at 28 months. Pulmonary hypertension and the composite end point developed

2013 EvidenceUpdates Controlled trial quality: uncertain

147. Cohort: Thrombolytic therapy with or without a vena cava filter results in a lower case fatality rate in unstable patients with acute pulmonary embolism

Cohort: Thrombolytic therapy with or without a vena cava filter results in a lower case fatality rate in unstable patients with acute pulmonary embolism Thrombolytic therapy with or without a vena cava filter results in a lower case fatality rate in unstable patients with acute pulmonary embolism | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) rate in unstable patients with acute pulmonary embolism Article Text Online articles Cohort Thrombolytic therapy with or without a vena cava filter results in a lower case fatality rate in unstable patients with acute pulmonary embolism Marie Méan 1 , Said A Ibrahim 2,3 Statistics from Altmetric.com Commentary on: Stein PD , Matta F . Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused . Context Acute pulmonary embolism (PE) is a major health problem

2013 Evidence-Based Medicine

148. Long-term prognostic value of residual pulmonary vascular obstruction at discharge in patients with intermediate- to high-risk pulmonary embolism Full Text available with Trip Pro

Long-term prognostic value of residual pulmonary vascular obstruction at discharge in patients with intermediate- to high-risk pulmonary embolism We evaluated prognostic value at 6 months of residual pulmonary vascular obstruction (RPVO) measured before discharge in patients with intermediate- or high-risk pulmonary embolism (PE).Prospective registry including 416 consecutive patients with intermediate- or high-risk PE who survived the acute phase. Patients with previous cardiopulmonary disease (...) were excluded. Perfusion lung scans were performed within 6-8 days after the onset of treatment. Residual pulmonary vascular obstruction was graded as the proportion of the lung not perfused. Primary objective was a combined endpoint at 6 months, including death, recurrent PE, and appearance of signs of heart failure. At 6 months, 32 patients (7.7%) had at least one adverse event: 12 deaths (2.9%), 12 recurrent PE (2.9%), and 14 (3.4%) heart failure. Independent predictors of combined endpoint were

2012 EvidenceUpdates

149. Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. Full Text available with Trip Pro

Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. To validate the use of the Wells clinical decision rule combined with a point of care D-dimer test to safely exclude pulmonary embolism in primary care.Prospective cohort study.Primary care across three different regions of the Netherlands (Amsterdam, Maastricht, and Utrecht).598 adults with suspected pulmonary embolism in primary care.Doctors scored patients (...) according to the seven variables of the Wells rule and carried out a qualitative point of care D-dimer test. All patients were referred to secondary care and diagnosed according to local protocols. Pulmonary embolism was confirmed or refuted on the basis of a composite reference standard, including spiral computed tomography and three months' follow-up.Diagnostic accuracy (sensitivity and specificity), proportion of patients at low risk (efficiency), number of missed patients with pulmonary embolism

2012 BMJ

150. Rivaroxaban - Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism

Rivaroxaban - Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism Common Drug Review CDEC Meeting – July 18, 2012 Notice of CDEC Final Recommendation – August 16, 2012 Page 1 of 5 © 2012 CADTH CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto – Bayer Inc.) New Indication: Deep Vein Thrombosis (Treatment) without Symptomatic Pulmonary Embolism Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be listed for the treatment of deep vein (...) thrombosis (DVT) in patients without symptomatic pulmonary embolism (PE), for a duration not to exceed six months. Reasons for the Recommendation: 1. In one large randomized controlled trial (RCT) of patients with acute symptomatic DVT without symptomatic PE (the EINSTEIN DVT trial), rivaroxaban was reported to be non- inferior to a regimen of enoxaparin plus a vitamin K antagonist (VKA) based on the incidence of recurrent DVT or PE. The majority of patients received treatment for six months or less

2012 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

151. Cook celect vena cava filter (Cook Medical Inc.) for prophylaxis and treatment of pulmonary embolism

Cook celect vena cava filter (Cook Medical Inc.) for prophylaxis and treatment of pulmonary embolism Cook celect vena cava filter (Cook Medical Inc.) for prophylaxis and treatment of pulmonary embolism Cook celect vena cava filter (Cook Medical Inc.) for prophylaxis and treatment of pulmonary embolism Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Cook celect (...) vena cava filter (Cook Medical Inc.) for prophylaxis and treatment of pulmonary embolism. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2012 Authors' conclusions Venous thromboembolism (VTE), the formation of blood clots in veins, is a leading cause of disability and death. The syndrome refers to both deep vein thrombosis (DVT) and pulmonary embolism (PE). Each year an estimated 300,000 to 600,000 people in the United States are affected by VTE (1 to 2 per 1000

2012 Health Technology Assessment (HTA) Database.

152. Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period

Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period - MCLINTOCK - 2012 - Australian and New Zealand Journal of Obstetrics and Gynaecology - Wiley Online Library Search within Search term Search term Opinion Recommendations for the diagnosis and treatment of deep venous (...) thrombosis and pulmonary embolism in pregnancy and the postpartum period National Women’s Health, Auckland City Hospital, Grafton, Auckland, New Zealand Department of Haematology, Prince of Wales Hospital, Sydney, New South Wales Clinical Haematology Department, Monash Medical Centre, Clayton Australian Centre for Blood Diseases, Monash University, Prahran, Victoria Discipline of Obstetrics and Gynaecology, University of Adelaide, Lyell McEwin Hospital Department of Obstetrics and Gynaecology, Women’s

2012 Clinical Practice Guidelines Portal

153. Pulmonary embolism and deep vein thrombosis. Full Text available with Trip Pro

assessment helps to identify patients with low clinical probability for whom the diagnosis of venous thromboembolism can be excluded solely with a negative result from a plasma D-dimer test. The diagnosis is usually confirmed with compression ultrasound showing deep vein thrombosis or with chest CT showing pulmonary embolism. Most patients with venous thromboembolism will respond to anticoagulation, which is the foundation of treatment. Patients with pulmonary embolism should undergo risk stratification (...) Pulmonary embolism and deep vein thrombosis. Pulmonary embolism is the third most common cause of death from cardiovascular disease after heart attack and stroke. Sequelae occurring after venous thromboembolism include chronic thromboembolic pulmonary hypertension and post-thrombotic syndrome. Venous thromboembolism and atherothrombosis share common risk factors and the common pathophysiological characteristics of inflammation, hypercoagulability, and endothelial injury. Clinical probability

2012 Lancet

154. Managing pulmonary embolism using prognostic models: future concepts for primary care Full Text available with Trip Pro

Managing pulmonary embolism using prognostic models: future concepts for primary care 22143233 2012 04 13 2018 11 13 1488-2329 184 3 2012 Feb 21 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Managing pulmonary embolism using prognostic models: future concepts for primary care. 305-10 10.1503/cmaj.110213 Geersing Geert-Jan GJ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands (...) . G.J.Geersing@umcutrecht.nl Oudega Ruud R Hoes Arno W AW Moons Karel G M KG eng Journal Article Research Support, Non-U.S. Gov't Review 2011 12 05 Canada CMAJ 9711805 0820-3946 0 Anticoagulants AIM IM Aged Anticoagulants therapeutic use Female Humans Male Models, Statistical Primary Health Care standards Prognosis Pulmonary Embolism diagnosis drug therapy therapy Risk Factors Secondary Prevention Severity of Illness Index 2011 12 7 6 0 2011 12 7 6 0 2012 4 14 6 0 ppublish 22143233 cmaj.110213 10.1503/cmaj

2012 EvidenceUpdates

155. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261) Overview | Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | Guidance | NICE Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Technology appraisal guidance [TA261] Published date: 25 July 2012 Share Guidance (...) on rivaroxaban (Xarelto) for treating deep vein thrombosis and preventing a pulmonary embolism or another deep vein thrombosis in adults. Guidance development process Is this guidance up to date? . We found nothing new that affects the recommendations in this guidance. Next review : This guidance will be reviewed if there is new evidence that is likely to affect the recommendations. Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration

2012 National Institute for Health and Clinical Excellence - Technology Appraisals

156. Are Thrombolytics Indicated for Pulmonary Embolism?

: 507-511. 5. Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347:1143-1150. 6. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest. 1990;98:1473-1479. 7. Arnesen BLH, Eie H, Hol R. A prospective study of streptokinase and heparin in the treatment of major (...) pulmonary embolism. Acta Med Scand Suppl. 1978;621:465-470. 8. PIOPED Investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED investigators. Chest. 1990;97:528-533. 9. Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. Br Med J. 1974;1:343-347. 10. Sasahara AA, Hyers TM, Cole CM, et al. The urokinase pulmonary embolism

2012 Annals of Emergency Medicine Systematic Review Snapshots

157. Randomised controlled trial: In selected lower risk patients with acute pulmonary embolism, outpatient treatment is not associated with increased risk of adverse outcomes compared with standard inpatient care

Randomised controlled trial: In selected lower risk patients with acute pulmonary embolism, outpatient treatment is not associated with increased risk of adverse outcomes compared with standard inpatient care In selected lower risk patients with acute pulmonary embolism, outpatient treatment is not associated with increased risk of adverse outcomes compared with standard inpatient care | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising (...) In selected lower risk patients with acute pulmonary embolism, outpatient treatment is not associated with increased risk of adverse outcomes compared with standard inpatient care Article Text Therapeutics Randomised controlled trial In selected lower risk patients with acute pulmonary embolism, outpatient treatment is not associated with increased risk of adverse outcomes compared with standard inpatient care Philip Stephen Wells Statistics from Altmetric.com Commentary on: Aujesky D , Roy PM

2012 Evidence-Based Medicine

158. Systematic review: Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefit

Systematic review: Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefit Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefit | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content (...) are here Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefit Article Text Therapeutics Systematic review Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefit Mark Crowther 1 , David G Gracia 2 Statistics from Altmetric.com

2012 Evidence-Based Medicine

159. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. Full Text available with Trip Pro

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism.In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism (...) % CI, 0.31 to 0.79; P=0.003). Rates of other adverse events were similar in the two groups.A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. (Funded by Bayer HealthCare and Janssen Pharmaceuticals; EINSTEIN-PE ClinicalTrials.gov number, NCT00439777.).

2012 NEJM Controlled trial quality: predicted high

160. Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study Full Text available with Trip Pro

Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study The new, high-sensitivity troponin T (hsTnT) assay may improve risk stratification of normotensive patients with acute pulmonary embolism (PE). We externally validated the prognostic value of hsTnT, and of the simplified Pulmonary Embolism Severity Index (sPESI), in a large multicenter

2012 EvidenceUpdates